---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-24-000039"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:01:39.808517+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio Q2 net loss $46.7M; cash $393.5M; ANB032 Phase 2b enrollment complete, data Dec 2024

## Summary
- Net loss of $46.7M ($1.71 per share) for Q2 2024, vs $39.8M loss ($1.50) in Q2 2023.
- Cash & investments $393.5M as of June 30, 2024; runway reiterated through year-end 2026.
- Completed enrollment (~200 patients) for ANB032 Phase 2b in atopic dermatitis; top-line data expected Dec 2024.
- Rosnilimab Phase 2b RA top-line data accelerated to Q1 2025; Phase 2 UC data now expected Q1 2026.
- IND for ANB033 (anti-CD122) accepted by FDA; Phase 1 trial initiation anticipated in Q4 2024.

## SEC filing metadata
- accession: 0001370053-24-000039
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005324000039/0001370053-24-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005324000039/anab-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-24-000039
- JSON: https://secwatch.observer/filing/0001370053-24-000039.json
- Plain text: https://secwatch.observer/filing/0001370053-24-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.